1. Introduction
===============

Drug-induced neuropathy is one of the main causes of peripheral neuropathies. This is of great importance because through an early diagnosis, significant recovery will occur after stopping the prescribed medication and administering the proper treatment. On the other hand, in many cases there is no specific treatment for idiopathic neuropathies ([@b1-epj-10-6527]). Neuropathic symptoms include sensory, motor and autonomic dysfunctions which depend on the type of the peripheral nerve involvement. Sensory symptoms include prickling, tingling, bunch-up and numbness. Patients with acquired neuropathy usually complain of positive neuropathic sensory symptoms while such symptoms are rarely mentioned in hereditary polyneuropathies ([@b2-epj-10-6527], [@b3-epj-10-6527]). Pain could have toxic, metabolic or ischemic causes. In such cases, symptoms like burning, freezing or throbbing could be experienced. Motor symptoms usually manifest as paresis. Autonomic symptoms include diarrhea, syncope, light-headedness, urinary problems, early satiety, constipation, dry mouth and dry eyes, diminished or excessive perspiration, and erectile dysfunction ([@b2-epj-10-6527]). Fortunately, drug-induced neuropathies are not that frequent (2--4%) ([@b4-epj-10-6527]). When acute side-effects manifest following consumption of a drug, it would be easy to make the link (most side-effects appear in this manner), but in cases such as peripheral neuropathy, it would take months or even years before any symptoms appear; hence, it is farfetched to find this kind of relation ([@b1-epj-10-6527], [@b3-epj-10-6527], [@b5-epj-10-6527]). Dying-back axonal involvement is the most common type of peripheral neuropathy following medication; since the neuronal cell body and proximal axon are intact, the patient recovers after stopping the stimulus, for instance cutting off medication. However, some drugs might involve the peripheral nerves in other ways, for instance involvement of myelin, autonomic nerves and nerve roots ([@b6-epj-10-6527]). Chemotherapy drugs, Metronidazole, Amiodarone, Hydralazine, Enalapril, Phenytoin, Allopurinol, and Colchicine might induce peripheral neuropathy ([@b1-epj-10-6527], [@b4-epj-10-6527]). However, the role of statins in peripheral neuropathy has not yet been definitively proven ([@b7-epj-10-6527]), and many studies have merely included case reports involving this condition ([@b8-epj-10-6527], [@b9-epj-10-6527]). Statins as Hydroxy-methyl-CoA Reductase (HMG-CoA) inhibitors lower the plasma cholesterol, especially Low-density lipoprotein (LDL), following the inhibition of intracellular cholesterol production ([@b6-epj-10-6527], [@b10-epj-10-6527]). Treatment indications with statins are hypercholesterolemia and prevention of cardiovascular diseases ([@b11-epj-10-6527]) that can lead to the reduction of morbidity and mortality ([@b6-epj-10-6527]). Therefore, considering their extensive usage, it is necessary to be aware of their side-effects. Muscle diseases are the most common side-effects of statins, which could manifest ranging from mild muscle weakness to severe rhabdomyolysis ([@b10-epj-10-6527], [@b12-epj-10-6527]--[@b14-epj-10-6527]). Peripheral neuropathy is a probable side-effect of these drugs. Due to the intrusive role of these drugs in the production of cholesterol, they might change the function and integrity of cell membranes, in which cholesterol plays a key role ([@b15-epj-10-6527]). Meanwhile, statins also inhibit an important enzyme in mitochondrial respiration named ubiquinone (Coenzyme Q10), which could in turn change the neurons' energy consumption ([@b3-epj-10-6527], [@b6-epj-10-6527], [@b15-epj-10-6527]--[@b17-epj-10-6527]). These are the probable mechanisms of the peripheral neuropathy. Electrodiagnostic tests are amongst the most important methods for diagnosis of peripheral neuropathy. These tests are used to confirm peripheral neuropathy, diagnose the axon or myelin involvement or both of them, as well as classify neuropathy as sensory, motor and sensorimotor, determining the location of the nerve injury and revealing the severity of peripheral nerve involvement ([@b2-epj-10-6527], [@b18-epj-10-6527]). Based on the pathophysiology of this adverse effect and our clinical experience, we attempted to evaluate the probable peripheral nerve dysfunctions amongst native Iranian patients with long-term history of statin consumption based on electrodiagnosis. To the best of our knowledge, there are no previous similar studies in this field.

2. Material and Methods
=======================

2.1. Patients and Settings
--------------------------

In this case-control study, a total of 39 qualified patients (sample size determined according to previous studies) were enrolled in a case group via simple random sampling. The study population was those who visited the physical medicine and rehabilitation outpatient clinics of Shiraz University of Medical Sciences, Shiraz, Iran in 2015. The control group consisted of 39 cases selected through the patients' relatives, friends and colleagues, who had never consumed such drugs and had never complained about any signs of peripheral neuropathy. Demographic data such as age, sex, height and weight of both groups were selected to be similar.

2.2. Selection criteria
-----------------------

Inclusion Criteria were age between 35--55 years, daily consumption of at least 10 mg simvastatin, and 10 mg atorvastatin and 20 mg lovastatin for more than six consecutive months. Exclusion Criteria were consumption of any drugs that have proven to cause peripheral neuropathy; history of cancer or chemotherapy, trauma and fractures in the upper and lower limbs, diabetes, hereditary neuropathies, anatomical and hereditary disorders in the upper and lower limbs, rheumatic disease and vasculitis, hepatopathy, digestive diseases such as celiac and inflammatory bowel syndrome, respiratory disease, thyroid disease, paraproteinemia, metabolic disease, exposure to various toxins and heavy metals, alcohol consumption, Lyme disease, HIV/AIDS, tuberculosis, leprosy, syphilis, B12 deficiency, uremia, space-occupying lesions in the upper and lower limbs, active radiculopathies; and finally various entrapment neuropathies such as carpal tunnel syndrome.

2.3. Procedure
--------------

After clinical examination of all subjects by a physician, especially their neuro-musculoskeletal systems and if they met the inclusion criteria, electrodiagnostic tests were performed by a specialist in physical medicine and rehabilitation ([@b18-epj-10-6527], [@b19-epj-10-6527]). Outcome evaluation was blinded. The calibration of the system was ensured. The nerve conduction study (NCS) was performed in normal room temperature (24 °C); while temperatures of the upper and lower limbs were at the standard degree for the test, which is 34 °C and 32 °C, respectively. Also, the limbs were not wet and no perspiration was observed. The EMG machine in use was a Medelec Synergy electromyography instrument (VIASYS HealthCare, Surrey, UK) and surface electrodes were used for both recording and stimulation. The grounding plate was placed on the same limb and supramaximal electrical stimulation was induced manually. Stimulation lasted for 0.1ms at the frequency of 1--0.2 Hz. Machine settings were as follows: Sweep speed: 2 ms/division; Sensitivity for sensory waves: 50 μv/division; Sensitivity for motor waves: 1mv/division; Filter: 2 Hz--2 kHz. Waves were evaluated for the tibial, peroneal, ulnar, and median motor nerves, as well as median, ulnar and sural sensory nerves. Nerve conduction velocity (NCV) was also measured for median, tibial and peroneal nerves. Placement methods for stimulation and recording electrodes and natural values of amplitude, latency and NCV for motor and sensory nerves of the upper and lower limbs are shown in [Table 1](#t1-epj-10-6527){ref-type="table"}. Regarding motor nerve conduction, the recording electrode recorded the compound muscle action potential (CMAP) of the relative muscle. Onset latency was defined as the period from the moment stimulation begins until the first wave was recorded. Regarding sensory nerve conduction, the recording electrode recorded the sensory nerve action potential (SNAP) of the relative muscle. Peak latency was defined as the period from stimulation until the appearance of the negative peak latency. Furthermore, the amplitudes of CMAP and SNAP waves were calculated based on the distance between baseline and the highest peak of the negative wave. We defined the criteria for peripheral neuropathy as below:

1.  Two abnormalities (velocity, amplitude, latency) in 2 nerves

2.  Two abnormalities in 3 asymmetrical nerves (mononeuritis multiplex)

3.  Two abnormalities in 3 symmetrical nerves (polyneuropathy)

2.4. Statistical analysis
-------------------------

The obtained values were analyzed using SPSS version 18 (SPSS Inc., Chicago, Illinois, USA). Descriptive statistics (means and standard deviations) were reported for each nerve conduction value. The t-test, Cochran's Q test and Fisher's exact test were used for analysis of the results. P\<0.05 was considered statistically significant.

2.5. Ethics
-----------

Written consent was obtained from all participants after explaining the study objectives. The study protocol was in accordance to the Helsinki Declaration of Bioethics and was approved by institutional review board.

3. Results
==========

The case group consisted of 39 individuals (25 men and 14 women) with a mean age of 47 and age range of 37--55 years. Average period of statin consumption in this group was eight months. There were 39 individuals (21 men and 18 women) in the control group with an average age of 49 and age range of 35--55. All values obtained from the NCS (amplitude, latency and NCV) were compared with the normal values for each nerve; results are displayed in [Table 2](#t2-epj-10-6527){ref-type="table"}. We calculated the means for different wave features (amplitude, latency and NCV), and made a comparison using an independent t-test, as shown in [Table 3](#t3-epj-10-6527){ref-type="table"}. According to [Table 3](#t3-epj-10-6527){ref-type="table"}, the mean differences were only significant for amplitudes of the peroneal motor nerve (p=0.048) and sural sensory nerve (p=0.036); regarding amplitude of the median sensory nerve (p=0.058), the amplitude of the ulnar sensory nerve (p=0.070), the amplitude of the tibial motor nerve (p=0.068) and the latency of the ulnar sensory nerve (p=0.064), even though statistically insignificant, were worth considering. No significant differences were observed in other cases.

4. Discussion
=============

In this study, no significant differences were observed between the groups regarding any of the definitions for peripheral neuropathy. However, the p-value (0.055) was close to significance for the first criteria \[2 abnormalities (velocity, amplitude, latency) in 2 nerves\]. Comparison of the mean differences for nerve features between the two groups revealed that only in two features obvious differences were observed: amplitude of the peroneal motor nerve (p=0.048) and amplitude of the sural sensory nerve (p=0.036). In four features, including amplitude of the median sensory nerve (p=0.058), amplitude of the ulnar sensory nerve (p=0.070), amplitude of the tibial motor nerve (p=0.068) and latency of the ulnar sensory nerve (p=0.064), even though the differences were not statistically significant, they might have become significant, had the study been conducted on a higher number of cases or among patients with longer periods of drug consumption. Since most of the differences were in amplitudes and the relative nerves were related to lower limbs, we can assume that these drugs mostly affected the axonal fibers and had little effect on the myelin sheaths of the studied nerves. These findings were consistent with our previous knowledge regarding the probability of peripheral neuropathy following drug consumption (axonal neuropathy) ([@b1-epj-10-6527], [@b20-epj-10-6527], [@b21-epj-10-6527]). Brenton West found that the prevalence of this type of neuropathy was 4--14 times higher among patients using statins ([@b22-epj-10-6527]) Gaist stated that patients on statins are 2.5 times more susceptible to polyneuropathy in comparison with the normal population ([@b23-epj-10-6527]). In a prospective study with electrodiagnostic follow-up, Pavel Otruba evaluated the peripheral nerves of the lower limbs among 42 patients with hyperlipidemia at the beginning of the statin consumption period and then at the 6^th^, 12^th^ and 24^th^ month, using the NCS criteria (tibial, peroneal, sural and superficial peroneal nerve features); at the end, they only found significant differences in the nerve conduction latency of the F wave for motor nerves, and concluded that "long-term use of statins could make visible changes in electrophysiological findings; however, these probable changes are clinically silent" ([@b12-epj-10-6527]). However, they did not evaluate the nerve response latency in their study. In the present study, even though we did not evaluate the F wave, nerve response latency was studied in the sensory and motor nerves of the upper and lower limbs; however, none of them showed a significant difference. In a cohort study, Davis showed that statin consumption could prevent distal sensory neuropathy in diabetic individuals. In their study, they used the Michigan Neuropathy Screening Instrument (MNSI) as the criteria for neuropathy ([@b24-epj-10-6527]). Nonetheless, it seems that future studies should use electrodiagnosis to confirm their findings. Conversely, in another study, Vaughan TB introduced a patient with type 1 diabetes (without any hyperlipidemia) who was on atorvastatin and had developed axonal sensory, motor and autonomic peripheral neuropathy. After discontinuation of the drug, the patient showed a significant clinical recovery in one week ([@b16-epj-10-6527]). One case of mononeuritis multiplex was observed in our case group based on the normal values presented in [Table 1](#t1-epj-10-6527){ref-type="table"}. However, that patient did not have any clinical complaints regarding peripheral neuropathy. There have been other case reports involving this phenomenon following statin consumption; for instance, Menahem introduced a patient who consumed simvastatin for approximately three years which had developed meralgia paresthetica, but after a few weeks being off the drug, the patient's symptoms vanished completely ([@b25-epj-10-6527]). Rosana H. Scola et al. found this phenomenon in a 63-year-old man following high doses of simvastatin; this patient had sensory and motor complaints ([@b26-epj-10-6527]). In an animal study on rats, Nitya N. Pathak revealed atorvastatin to be effective in neuropathic pain reduction. This effect is caused by changes in enzymatic and non-enzymatic systems of antioxidants (malondialdehyde and super-oxide anions are reduced following atorvastatin consumption) ([@b11-epj-10-6527]). Furthermore, through sympathetic skin response (SSR) testing, Ziajka reported the occurrence of peripheral neuropathy in thin fibers following statin consumption, and showed the test results to return to normal after drug cessation ([@b27-epj-10-6527]). In our study, we used the conventional techniques for nerve conduction, which only evaluates large nerve fibers, but the SSR test can be used to evaluate thin fibers. Most reports on statin-induced neuropathy propose the improvement of clinical symptoms and electrophysiological tests after stopping the drug; however, Jeppesen stated that symptoms had lasted longer in four out of seven patients with the disease, by using quantitative sensory testing (QST); he had presumed that the probable cause was longer periods of consumption or longer periods of having symptoms before being cut off ([@b28-epj-10-6527]).

5. Conclusions
==============

With regard to the above-mentioned findings, it can be concluded that statin consumption can cause changes in the peripheral nerves with a preference of axonal involvement; however, in many cases, these changes are not significant enough to cause visible clinical symptoms, especially when the consumption period is not that long. Considering the variety of reports regarding the effects of these drugs on the peripheral nerves, we suggest further, more extensive studies on patients with long-term statin consumption using different methods of peripheral nerve evaluation such as NCS, QST, and SSR. A limitation of this study was the small number of patients. Also, we recommend that patients with long-term use should become aware of this condition's symptoms and visit their doctors for diagnostic evaluations; we also recommend that the physicians should ask questions regarding these symptoms in their regular check-ups. Also, future studies can focus on larger samples. As the prevalence of neuropathy was generally low in our sample population, application of inverse sampling method could yield more reliable results. We could not predict this point before conduction of the study and therefore it is suggested for future studies.
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###### 

Placement methods for stimulation and recording electrodes and natural values of amplitude, latency and NCV for motor and sensory nerves of the upper and lower limbs

  Nerve conduction study         Stimulation site                                                                                                                                                                                                   Recording site                         Amplitude   Onset latency (ms) site 1   Conduction velocity (m/s)
  ------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------- ----------- --------------------------- ---------------------------
  Median motor response          The wrist, somewhere between the palmaris longus and flexor carpi radialis tendons, 7 cm proximal to recording site (active electrode)                                                                             The abductor pollicis brevis muscle    ≥4 mv       ≤4.4                        \-
  Ulnar motor response           The wrist, next to the tendon of the flexor carpi ulnaris muscle, 7 cm proximal to recording site (active electrode)                                                                                               The abductor digiti minimi muscle      ≥6 mv       ≤3.3                        \-
  Tibial motor response          Site 1: The medial side of the ankle, higher and behind the medial malleolus, 9 cm proximal to the recording site (active electrode); site 2: the middle section of the popliteal region, on the popliteal pulse   The abductor hallucis muscle           ≥4 mv       ≤5.8                        ≥41
  Deep peroneal motor response   Site 1: The ankle, slightly lateral to the tendon of the tibialis anterior muscle, 9 cm proximal to the recording site (active electrode); site 2: under the head of the fibula, one or two fingerbreadths lower   The extensor digitorum brevis muscle   ≥2 mv       ≤6.5                        ≥44
  Median sensory response        Site 1: the wrist, somewhere between the palmaris longus and flexor carpi radialis tendons, 14 cm proximal to active electrode; site 2: the palm, 7 cm proximal to the recording site (active electrode)           Palmar surface of the middle finger    ≥20 μv      ≤3.5                        ≥50
  Ulnar sensory response         The medial side of the wrist, next to the tendon of the flexor carpi ulnaris muscle, 11 cm proximal to the recording site (active electrode)                                                                       Palmar surface of the 5^th^ finger     ≥17 μv      ≤3.1                        \-
  Sural sensory response         Posterior leg, 14 cm more proximal from the recording site, somewhere between the posterior and lateral section of the calf muscle                                                                                 Behind the lateral malleolus           ≥6 μv       ≤4.4                        \-

mV: millivolt; ms: millisecond; m/s: meter/second; μv: microvolt

###### 

Comparison of the case and control groups based on the occurrence of neuropathy

  Definition for neuropathy                                           Control (n=39)   Case (n=39)   p-value
  ------------------------------------------------------------------- ---------------- ------------- ---------
  2 abnormalities in 2 nerves                                         0                5             0.055
  2 abnormalities in 3 nerves (mononeuritis multiplex)                0                1             1
  2 abnormalities in at least 3 symmetrical nerves (polyneuropathy)   0                0             \-

###### 

Comparison of means for different nerve features and their results

  Nerve                                        Group         Mean±SD       p-value
  -------------------------------------------- ------------- ------------- ---------
  Median motor amplitude (mv)                  Case          8.33±1.74     0.226
  Control                                      8.65±1.47                   
  Median motor latency (ms)                    Case          3.763±0.26    0.900
  Control                                      3.758±0.24                  
  Median sensory amplitude (μv)                Case          22.401±4.48   0.058
  Control                                      23.667±3.74                 
  Median sensory latency (ms)                  Case          3.357±0.18    0.838
  Control                                      3.351±0.16                  
  Median conduction velocity (sensory) (m/s)   Case          52.04±3.46    0.220
  Control                                      52.22±2.72                  
  Ulnar motor amplitude (mv)                   Case          7.399±0.92    0.215
  Control                                      7.446±1.13                  
  Ulnar motor latency (ms)                     Case          2.79±0.27     0.903
  Control                                      2.79±0.25                   
  Ulnar sensory amplitude (μv)                 Case          21.132±3.94   0.070
  Control                                      22.492±3.67                 
  Ulnar sensory latency (ms)                   Case          2.776±0.31    0.064
  Control                                      2.687±0.27                  
  Tibial motor amplitude (mv)                  Case          5.243±1.27    0.068
  Control                                      5.558±1.00                  
  Tibial motor latency (ms)                    Case          4.60±0.56     0.169
  Control                                      4.71±0.40                   
  Tibial conduction velocity (motor) (m/s)     Case          42.67±2.25    0.610
  Control                                      42.83±1.79                  
  Peroneal motor amplitude (mv)                Case          2.763±1.06    0.048
  Control                                      2.515±0.64                  
  Peroneal motor latency (ms)                  Case          4.45±0.63     0.827
  Control                                      4.43±0.60                   
  Peroneal conduction velocity (motor) (m/s)   Case          48.09±4.62    0.151
  Control                                      47.15±3.38                  
  Sural amplitude (μv)                         Case          8.15±1.91     0.036
  Control                                      9.03±2.72                   
  Sural latency (ms)                           Case          3.601±0.50    0.134
  Control                                      3.519±0.49                  

mv: millivolt; ms: millisecond; m/s: meter/second; μv: microvolt; SD: Standard deviation
